Nautilus Biotechnology (NAUT) Non Operating Income (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Non Operating Income of $1.3 million for Q2 2026, down 9.36% sequentially from $1.4 million in Q1 2026, and down 37.16% YoY from $2.1 million in Q2 2025.
Nautilus Biotechnology (NAUT) Non Operating Income (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Non Operating Income for 7 years, with the latest figure at $1.3 million in Q2 2026.
- Quarterly Non Operating Income fell 37.16% year-over-year to $1.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.3 million (down 33.03% YoY) and the FY2025 annual result came in at $7.9 million, down 27.01% from the prior year.
- Non Operating Income fell to $1.3 million in Q2 2026 per NAUT's latest filing, from $1.4 million in the prior quarter.
- Over five years, Non Operating Income peaked at $3.2 million in Q2 2023 and troughed at $264000.0 in Q1 2022.
- A 5-year average of $2.2 million and a median of $2.3 million in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2026: Non Operating Income soared 4993.75% in 2022, then slumped 37.16% in 2026.
- Over 5 years, Non Operating Income stood at $2.9 million in 2022, then climbed by 5.06% to $3.0 million in 2023, then fell by 19.85% to $2.4 million in 2024, then plunged by 31.96% to $1.7 million in 2025, then slipped by 20.98% to $1.3 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.3 million, $1.4 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 1.44 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | 3.03 Mn |
| Sep 30, 2023 | 3.20 Mn |
| Jun 30, 2023 | 3.22 Mn |
| Mar 31, 2023 | 3.10 Mn |
| Dec 31, 2022 | 2.89 Mn |
| Sep 30, 2022 | 1.89 Mn |
| Jun 30, 2022 | 783,000.00 |
| Mar 31, 2022 | 264,000.00 |
| Dec 31, 2021 | 161,000.00 |
| Sep 30, 2021 | 136,000.00 |